Navidea posts revenue declines, net loss increases in Q2

Radiopharmaceutical developer Navidea Biopharmaceuticals reported a declin...Read more on AuntMinnie.comRelated Reading: Navidea highlights research on melanoma, oral cancer Navidea touts clinical study using PET/CT for HIV infection Navidea touts early results of RA study Navidea secures Indian regulatory approval for Lymphoseek NYSE accepts Navidea bid to comply with stock listing rules
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news